Skip to content

Study · In vitro (cells) · 2004

1 result

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.

Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G

European journal of endocrinology1 Jul 2004Cited by 63 (Europe PMC)

PMID15248835 (opens in a new tab)DOI10.1530/eje.0.1510141 (opens in a new tab)PepBankPUB-15248835
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In endometrial and ovarian cancer cells, cetrorelix retained antiproliferative effects after GnRH-I receptor knockout.

    In plain wordsIn cells, cetrorelix still reduced cancer cell proliferation after GnRH-I receptor knockout.

    Peptide
    Cetrorelix
    Outcome
    Not applicableAntiproliferative activity after GnRH-I receptor knockout
    Study

    humann: not reported in source

    Endometrial and ovarian cancer cell lines
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that, after knockout of the GnRH-I receptor, the antiproliferative effects of the GnRH-I agonist triptorelin were abrogated, whereas those of the GnRH-I antagonist cetrorelix and of GnRH-II persisted.
    1 context sentence
    Summary · context
    in a panel of endometrial and ovarian cancer cell lines expressing GnRH-I receptors, in the SK-OV-3 ovarian cancer cell line that does not express GnRH-I receptors, and in four GnRH-I receptor positive GnRH-I receptor knockout cell lines.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.